Sponsors (4)
The bill accelerates patient access to lower-cost generics and biosimilars and reduces litigation uncertainty for applicants by limiting method-of-use patent enforcement tied to labeling, but it does so at the cost of weakening some patent protections, potentially reducing innovation incentives and creating retroactive legal uncertainty.
Patients with chronic conditions and small-business generic/biosimilar manufacturers: manufacturers can seek FDA approval and market products without facing method-of-use patent suits when they follow labeling disclosures, enabling earlier market entry, stronger competition, and likely lower drug prices and out-of-pocket costs.
Hospitals, health systems, generic applicants, and courts: the bill clarifies legal definitions (labeling, promotion, commercial marketing, PHSA biologic terms) and the scope of safe-harbor for method-of-use claims, reducing litigation uncertainty and making regulatory and legal outcomes more predictable.
Patent holders and drug innovators: owners of method-of-use patents will lose an enforcement tool, which could reduce incentives or returns for some drug development focused on patented indications.
Patients with chronic conditions and the public: manufacturers could narrowly tailor labeling to avoid infringement while still encouraging off-label use in practice, potentially undermining the practical scope of patent protections and exposing patients to promotional practices that skirt original patent limits.
Small businesses, hospitals, and parties in litigation: retroactive application of the rule could reopen settled cases or alter outcomes of pending litigation, creating legal uncertainty, potential reopening costs, and administrative burdens for courts and stakeholders.
Based on analysis of 2 sections of legislative text.
Creates a patent safe harbor allowing certain generic and biosimilar filings, marketing, and labeling when applicants disclose patented method‑of‑use information to FDA and avoid referencing those patented uses.
Official title: Amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products.
Introduced January 9, 2025 by John Wright Hickenlooper · Last progress January 9, 2025
Creates a statutory safe harbor in patent law that shields certain activities by generic drug and biosimilar applicants and sellers from infringement claims tied to method‑of‑use patents when the applicant makes required statements to FDA and limits labeling/promotion accordingly. The protection covers ANDA, certain 505(b)(2) and NADAs, and biosimilar BLA pathways, and it applies retroactively and prospectively. The law defines when filing, marketing, labeling, and promotion are protected, ties the scope to what uses were disclosed to FDA, cross‑references existing FDA/PHSA definitions, and restricts the safe harbor if the labeling or promotion references patented conditions of use that were identified to FDA.